A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis

Inclusion Criteria: * Signed informed consent including data protection declaration prior to study participation * Subjects with confirmed cirrhosis (by biopsy, ultrasound, and/or laboratory examinations) * Ascites Grade II or Grade III at screening currently treated with at least one diuretic or the subject is considered intolerant to diuretics in the investigator's opinion Exclusion Criteria: * Age \<18 years of age * Any of the following laboratory findings at the time of screening * Serum creatinine level \>1.5mg/dL (\>132 µmol/L) * Serum Na+ \< 125 meq/L * Serum K+ ≥ 5.5 meq/L * Serum bilirubin ≥ 5 mg/dL (85.5 µmol/L) * INR \>3.0 * Women of childbearing potential with no effective contraceptive method (women of childbearing potential \[pre-menopausal, not surgically sterile for at least 3 months prior to the time of screening\] must have a confirmed negative serum β-hCG pregnancy test prior to enrolment and at Baseline Visit. They must use an effective contraceptive method throughout the study, and agree to repeat serum β-hCG pregnancy tests at designated visits) * Pregnancy or lactation * Systolic blood pressure \<90 mmHg or diastolic blood pressure \<60 mmHg * Sepsis and/or uncontrolled bacterial infection * Current or recent documented nephrotoxicity (within 4 weeks) * Hepatic Encephalopathy above grade 1 * History of variceal bleeding in the last 2 months * Suspicion of active alcohol consumption in the last 3 months * History of liver or kidney transplantation * History of Transjugular Intrahepatic Portosystemic Shunt (TIPS) * Suspected occlusive portal vein or splenic vein thrombosis * Hepatocellular carcinoma (HCC) beyond the Milan criteria * Acute Liver Failure or superimposed acute liver injury due to drugs (e.g., acetaminophen), dietary supplements, herbal preparations, viral hepatitis, or toxins * Severe cardiovascular disease, including, but not limited to, unstable angina, pulmonary oedema, congestive heart failure * Current or recent (within 30 days) renal replacement therapy (RRT) * If on beta-blockers, a change in dose or drug within last 15 days prior to screening * Use of any other endothelin receptor antagonist, octreotide, midodrine, terlipressin in last 15 days prior to screening * Known hypersensitivity to contrast-media * Any clinically significant abnormality identified on physical examination, laboratory tests, ECG or vital signs at the time of screening that in the judgment of the investigator or any sub-investigator would preclude safe completion of the study or constrains the assessment of efficacy * Known sensitivity to ambrisentan or any of the excipients of the formulation * Participation in other clinical research involving investigational medicinal products within 30 days of enrolment * Subjects who have difficulties in understanding the language in which the study information is given * Subjects who do not agree to the transmission of their anonymous data within the liability of documentation and notification * Staff of the study centre, staff of the sponsor or Clinical Research Organization (CRO), the investigator himself or close relatives of the investigator. Cardiac and Pulmonary Haemodynamic Study exclusion Criteria: Subjects fulfilling any of the exclusion criteria below may participate in the study, but will not undergo cardiac and pulmonary catheterisation: * Significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate \< 45 beats per minute or atrial fibrillation/flutter with sustained ventricular response of \> 90 beats per minute at rest, or Long QT syndrome or QTc \> 450 ms * Significant left ventricular outflow tract obstructions (e.g., severe valvular aortic stenosis, obstructive cardiomyopathy), severe mitral stenosis, restrictive amyloid myocardiopathy, acute myocarditis * Severe aortic insufficiency or severe mitral regurgitation for which surgical or percutaneous intervention is indicated * Major neurologic event including cerebrovascular events, within 30 days prior to screening * Clinical evidence of acute coronary syndrome currently or within 30 days prior to screening * Permanent pacemaker, cardiac resynchronisation device or implantable cardioverter-defibrillator in situ